Home Growth Disorders Skytrofa
Ascendis Pharma

Skytrofa

lonapegsomatropin-tcgd, The first and only FDA-approved once-weekly growth hormone treatment for pediatric patients with growth hormone deficiency.

About Skytrofa

Once-Weekly Growth Hormone Therapy

Skytrofa utilizes Ascendis Pharma's proprietary TransCon technology to deliver a sustained-release prodrug of somatropin, providing steady and predictable growth hormone levels throughout the week with a single weekly injection.

  • First and only FDA-approved once-weekly somatropin
  • TransCon technology for steady, predictable release
  • Approved for pediatric patients ≥1 year with GHD
  • Reduces injection burden from daily to once weekly
  • Exclusive Self-pay price option available
Skytrofa Self-Pay Program

Ocean Breeze Healthcare offers an exclusive Skytrofa self-pay price option. Contact us to learn more about eligibility and enrollment.

1×

Weekly Injection

vs. 365 daily injections

TransCon Technology
Steady, predictable growth hormone release throughout the week
Downloads

Patient & Clinical Resources

Self-Pay Program Information
PDF Document
Download Fill Online
Patient Consent Form
PDF Document
Download Fill Online
Back to Growth Disorders
Traveling with your medication? This medication requires refrigeration. Our partner 4AllFamily offers insulin coolers and medical travel cases to keep your medication safe wherever you go.
Shop Now

Ready to Get Started with Skytrofa?

Contact our team to learn about the self-pay program, insurance coverage, or to have your provider submit a prescription.

Contact Us (800) 219-5920